<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03804320</url>
  </required_header>
  <id_info>
    <org_study_id>Protocollo SRM Sorv Attiva</org_study_id>
    <nct_id>NCT03804320</nct_id>
  </id_info>
  <brief_title>Protocol Active Surveillance Small Renal Masses (SRMs)</brief_title>
  <official_title>Sorveglianza Attiva Dei Tumori Renali T1a Uguali o Inferiori a 2 cm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study of active surveillance, non-randomized, multicentric, in asymptomatic&#xD;
      patients over the age of 50 years, not affected by other tumors, with occasional diagnosis of&#xD;
      single monolateral solid renal mass equal to or less than 2 cm of diameter. Diagnosis will be&#xD;
      performed with chest CT abdomen with contrast and / or MRI abdomen with Gadolinium (Gd);&#xD;
      during the first year of active surveillance, the patient's status will be evaluated at 3, 6,&#xD;
      9 and 12 months from the diagnosis and, subsequently, according to the schedule of events&#xD;
      shown in the table &quot;Event Planning&quot; At the end of the 5 years of follow up, the patient will&#xD;
      be entrusted to his / her own treating physician, with indication to perform abdomen and&#xD;
      chest x-ray echography every 6 months and thoracic abdomen TAC with contrast and / or MRI&#xD;
      abdomen with (Gd) every 2 years up to 10 years from instrumental radiological diagnosis and&#xD;
      registration and communication of the possible date of death and cause The primary caregivers&#xD;
      and the patient will be contacted annually by the promoter center of the study at the end of&#xD;
      the first 5 years of study follow up and the data will be entered in the database by the&#xD;
      promoter center. The indication to surgical treatment or ablative treatment will be&#xD;
      considered in the following cases: 1. appearance of metastasis 2. increase of the maximum&#xD;
      diameter of the renal mass equal to or greater than 4 cm 3. time of doubling of the tumor&#xD;
      mass size less than or equal to 12 months 4. appearance of symptoms associated with renal&#xD;
      disease (pain, haematuria) 5. appearance of paraneoplastic syndrome (fever, cachexia,&#xD;
      hypercalcemia, polycythemia, ranulocytosis) 6. willingness expressed by the patient to&#xD;
      undergo surgery or ablative operation In the presence of at least one of the aforementioned&#xD;
      criteria, the attending physician can evaluate the possible execution of renal biopsy. The&#xD;
      finding of renal biopsy proved negative for neoplasia may allow the continuation of the&#xD;
      active surveillance procedure undertaken, independently indi - ding from the presence of one&#xD;
      of the above mentioned criteria. If the renal biopsy is negative, the therapeutic decision&#xD;
      (continuation of the follow up within the protocol in question, surgery or exit from the&#xD;
      protocol) will be agreed between the patient and the patient. In the case of a positive renal&#xD;
      biopsy for renal neoplasia, the patient may be a candidate for renal tumorectomy / radical&#xD;
      nephrectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2015</start_date>
  <completion_date type="Anticipated">December 11, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the therapeutic efficacy of active surveillance for small renal masses</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluate the therapeutic efficacy of active surveillance in patients with diagnosis of small renal tumor masses equal to or less than 2 cm in diameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the proportion of patients who do not undergone active treatment</measure>
    <time_frame>10 years</time_frame>
    <description>Proportion of patients who do not perform tumorectomy , tumor ablation or nephrectomy on the number of eligible patients that have been monitored for 12 months or more or have undergone surgery within 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and nature of disease progression during the period active surveillance</measure>
    <time_frame>10 years</time_frame>
    <description>Determine the incidence and nature of disease progression during the period of active surveillance; determine the annual growth rate of SRMs equal to or less than 2 cm of diameter; evaluate the appearance of symptoms associated with the disease (pain, haematuria) or syndrome paraneoplasty (fever, cachexia, hypercalcemia, polycythemia, granulocytosis); establish possible factors clinical, pathological and biological predictive of local or metastatic disease progression or that require surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disease progression</measure>
    <time_frame>10 years</time_frame>
    <description>The disease progression is defined as the growth of the maximum diameter of the renal mass equal to or more than 4 cm or doubling the tumor volume over a period of time ≤ 12 months. It is considered sign of progression also the vascular invasion, with the appearance of thrombosis of the renal vein or of the inferior vena cava;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with small renal masses</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Surveillance</intervention_name>
    <arm_group_label>Patients with small renal masses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ability to read, understand and interpret an informed consent;&#xD;
&#xD;
          2. voluntary subscription of the active surveillance protocol through written informed&#xD;
             consent; 3) age over 50 years;&#xD;
&#xD;
        4) diagnosis of monolateral, monofocal, and first-rate solid renal mass less than 2 cm; 5)&#xD;
        absence of symptoms due to renal tumor pathology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with a history of previous renal neoplasia;&#xD;
&#xD;
          2. monorenal patients;&#xD;
&#xD;
          3. patients with hereditary renal tumors (such as tuberous sclerosis and Von Hippel&#xD;
             Lindau syndrome, etc.);&#xD;
&#xD;
          4. patients with metastasis;&#xD;
&#xD;
          5. patients suffering from immunodepressive diseases;&#xD;
&#xD;
          6. patients on concomitant therapy with chemotherapeutic agents or systemic&#xD;
             immunosuppressants;&#xD;
&#xD;
          7. patients with life expectancy of less than 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Bertini</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Carenzi</last_name>
    <email>carenzi.cristina@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberto Bertini</last_name>
    <phone>+390226437267</phone>
    <email>bertini.roberto@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Bertini</last_name>
      <phone>+390226437267</phone>
      <email>bertini.roberto@hsr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum In: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004 Feb 15;100(4):738-45. doi: 10.1002/cncr.20025.</citation>
    <PMID>14770429</PMID>
  </reference>
  <reference>
    <citation>Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, Kaouk JH, Gill IS, Campbell SC. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010 Jul 1;116(13):3119-26. doi: 10.1002/cncr.25184.</citation>
    <PMID>20564627</PMID>
  </reference>
  <reference>
    <citation>Tada S, Yamagishi J, Kobayashi H, Hata Y, Kobari T. The incidence of simple renal cyst by computed tomography. Clin Radiol. 1983 Jul;34(4):437-9. doi: 10.1016/s0009-9260(83)80238-4.</citation>
    <PMID>6872451</PMID>
  </reference>
  <reference>
    <citation>Lane BR, Chen H, Morrow M, Anema JG, Kahnoski RJ. Increasing use of kidney sparing approaches for localized renal tumors in a community based health system: impact on renal functional outcomes. J Urol. 2011 Oct;186(4):1229-35. doi: 10.1016/j.juro.2011.05.081. Epub 2011 Aug 17.</citation>
    <PMID>21849192</PMID>
  </reference>
  <reference>
    <citation>Thompson RH, Kaag M, Vickers A, Kundu S, Bernstein M, Lowrance W, Galvin D, Dalbagni G, Touijer K, Russo P. Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol. 2009 Mar;181(3):993-7. doi: 10.1016/j.juro.2008.11.017. Epub 2009 Jan 16.</citation>
    <PMID>19150552</PMID>
  </reference>
  <reference>
    <citation>Dulabon LM, Lowrance WT, Russo P, Huang WC. Trends in renal tumor surgery delivery within the United States. Cancer. 2010 May 15;116(10):2316-21. doi: 10.1002/cncr.24965.</citation>
    <PMID>20225227</PMID>
  </reference>
  <reference>
    <citation>Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG; Practice Guidelines Committee of the American Urological Association. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct;182(4):1271-9. doi: 10.1016/j.juro.2009.07.004. Epub 2009 Aug 14. No abstract available.</citation>
    <PMID>19683266</PMID>
  </reference>
  <reference>
    <citation>Klinghoffer Z, Tarride JE, Novara G, Ficarra V, Kapoor A, Shayegan B, Braga LH. Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. Can Urol Assoc J. 2013 Mar-Apr;7(3-4):108-13. doi: 10.5489/cuaj.502.</citation>
    <PMID>23671525</PMID>
  </reference>
  <reference>
    <citation>Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, Weight CJ, Campbell SC. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007 Aug;178(2):429-34. doi: 10.1016/j.juro.2007.03.106. Epub 2007 Jun 11.</citation>
    <PMID>17561141</PMID>
  </reference>
  <reference>
    <citation>Remzi M, Ozsoy M, Klingler HC, Susani M, Waldert M, Seitz C, Schmidbauer J, Marberger M. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006 Sep;176(3):896-9. doi: 10.1016/j.juro.2006.04.047.</citation>
    <PMID>16890647</PMID>
  </reference>
  <reference>
    <citation>Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003 Dec;170(6 Pt 1):2217-20. doi: 10.1097/01.ju.0000095475.12515.5e.</citation>
    <PMID>14634382</PMID>
  </reference>
  <reference>
    <citation>Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S, Kirkali Z, Marberger M, Patard JJ, Staehler M, Uzzo RG. Contemporary management of small renal masses. Eur Urol. 2011 Sep;60(3):501-15. doi: 10.1016/j.eururo.2011.05.044. Epub 2011 Jun 1.</citation>
    <PMID>21664040</PMID>
  </reference>
  <reference>
    <citation>Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4. doi: 10.1093/jnci/djj362.</citation>
    <PMID>16985252</PMID>
  </reference>
  <reference>
    <citation>Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008 Jun;179(6):2146-51; discussion 2151. doi: 10.1016/j.juro.2008.01.101. Epub 2008 Apr 18.</citation>
    <PMID>18423735</PMID>
  </reference>
  <reference>
    <citation>Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, Jewett MA, Greenberg RE, Uzzo RG. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012 Feb 15;118(4):997-1006. doi: 10.1002/cncr.26369. Epub 2011 Jul 15.</citation>
    <PMID>21766302</PMID>
  </reference>
  <reference>
    <citation>Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009 Mar;181(3):1020-7; discussion 1027. doi: 10.1016/j.juro.2008.11.023. Epub 2009 Jan 16.</citation>
    <PMID>19150563</PMID>
  </reference>
  <reference>
    <citation>Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, Tanguay S, Rendon RA, Gleave ME, Drachenberg DE, Chow R, Chung H, Chin JL, Fleshner NE, Evans AJ, Gallie BL, Haider MA, Kachura JR, Kurban G, Fernandes K, Finelli A. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011 Jul;60(1):39-44. doi: 10.1016/j.eururo.2011.03.030. Epub 2011 Apr 1.</citation>
    <PMID>21477920</PMID>
  </reference>
  <reference>
    <citation>Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, Jewett MA, Klotz L, Rendon RA. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol. 2011 May;59(5):863-7. doi: 10.1016/j.eururo.2011.02.023. Epub 2011 Feb 22.</citation>
    <PMID>21353376</PMID>
  </reference>
  <reference>
    <citation>Ozsoy M, Klatte T, Waldert M, Remzi M. Surveillance for the management of small renal masses. Adv Urol. 2008;2008:196701. doi: 10.1155/2008/196701.</citation>
    <PMID>18704192</PMID>
  </reference>
  <reference>
    <citation>Patel N, Cranston D, Akhtar MZ, George C, Jones A, Leiblich A, Protheroe A, Sullivan M. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int. 2012 Nov;110(9):1270-5. doi: 10.1111/j.1464-410X.2012.11130.x. Epub 2012 May 4.</citation>
    <PMID>22564495</PMID>
  </reference>
  <reference>
    <citation>Barrisford GW, Singer EA, Rosner IL, Linehan WM, Bratslavsky G. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol. 2011;2011:658767. doi: 10.1155/2011/658767. Epub 2011 Aug 22.</citation>
    <PMID>22312516</PMID>
  </reference>
  <reference>
    <citation>Walther MM, Choyke PL, Glenn G, Lyne JC, Rayford W, Venzon D, Linehan WM. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999 May;161(5):1475-9. doi: 10.1016/s0022-5347(05)68930-6.</citation>
    <PMID>10210376</PMID>
  </reference>
  <reference>
    <citation>Ayati M, Nikfallah A, Jabalameli P, Najjaran Tousi V, Noroozi M, Jamshidian H. Extensive surgical management for renal tumors with inferior vena cava thrombus. Urol J. 2006 Fall;3(4):212-5.</citation>
    <PMID>17559043</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.</citation>
    <PMID>3558716</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Roberto Bertini</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Kidney cancer</keyword>
  <keyword>Active surveillance</keyword>
  <keyword>Small renal masses</keyword>
  <keyword>Partial nephrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03804320
org study id: Protocollo SRM Sorv Attiva
nct id: NCT03804320
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
Prospective study of active surveillance, non-randomized, multicentric, in asymptomatic
      patients over the age of 50 years, not affected by other tumors, with occasional diagnosis of
      single monolateral solid renal mass equal to or less than 2 cm of diameter. Diagnosis will be
      performed with chest CT abdomen with contrast and / or MRI abdomen with Gadolinium (Gd);
      during the first year of active surveillance, the patient's status will be evaluated at 3, 6,
      9 and 12 months from the diagnosis and, subsequently, according to the schedule of events
      shown in the table "Event Planning" At the end of the 5 years of follow up, the patient will
      be entrusted to his / her own treating physician, with indication to perform abdomen and
      chest x-ray echography every 6 months and thoracic abdomen TAC with contrast and / or MRI
      abdomen with (Gd) every 2 years up to 10 years from instrumental radiological diagnosis and
      registration and communication of the possible date of death and cause The primary caregivers
      and the patient will be contacted annually by the promoter center of the study at the end of
      the first 5 years of study follow up and the data will be entered in the database by the
      promoter center. The indication to surgical treatment or ablative treatment will be
      considered in the following cases: 1. appearance of metastasis 2. increase of the maximum
      diameter of the renal mass equal to or greater than 4 cm 3. time of doubling of the tumor
      mass size less than or equal to 12 months 4. appearance of symptoms associated with renal
      disease (pain, haematuria) 5. appearance of paraneoplastic syndrome (fever, cachexia,
      hypercalcemia, polycythemia, ranulocytosis) 6. willingness expressed by the patient to
      undergo surgery or ablative operation In the presence of at least one of the aforementioned
      criteria, the attending physician can evaluate the possible execution of renal biopsy. The
      finding of renal biopsy proved negative for neoplasia may allow the continuation of the
      active surveillance procedure undertaken, independently indi - ding from the presence of one
      of the above mentioned criteria. If the renal biopsy is negative, the therapeutic decision
      (continuation of the follow up within the protocol in question, surgery or exit from the
      protocol) will be agreed between the patient and the patient. In the case of a positive renal
      biopsy for renal neoplasia, the patient may be a candidate for renal tumorectomy / radical
      nephrectomy.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Evaluate the therapeutic efficacy of active surveillance for small renal masses
time frame: 10 years
description: Evaluate the therapeutic efficacy of active surveillance in patients with diagnosis of small renal tumor masses equal to or less than 2 cm in diameter.
measure: Evaluate the proportion of patients who do not undergone active treatment
time frame: 10 years
description: Proportion of patients who do not perform tumorectomy , tumor ablation or nephrectomy on the number of eligible patients that have been monitored for 12 months or more or have undergone surgery within 12 months
measure: Incidence and nature of disease progression during the period active surveillance
time frame: 10 years
description: Determine the incidence and nature of disease progression during the period of active surveillance; determine the annual growth rate of SRMs equal to or less than 2 cm of diameter; evaluate the appearance of symptoms associated with the disease (pain, haematuria) or syndrome paraneoplasty (fever, cachexia, hypercalcemia, polycythemia, granulocytosis); establish possible factors clinical, pathological and biological predictive of local or metastatic disease progression or that require surgery.
measure: Evaluation of disease progression
time frame: 10 years
description: The disease progression is defined as the growth of the maximum diameter of the renal mass equal to or more than 4 cm or doubling the tumor volume over a period of time ≤ 12 months. It is considered sign of progression also the vascular invasion, with the appearance of thrombosis of the renal vein or of the inferior vena cava;
arm group label: Patients with small renal masses
arm group type: Other
description: Active surveillance
intervention type: Other
intervention name: Active Surveillance
arm group label: Patients with small renal masses
criteria: 
gender: All
minimum age: 50 Years
maximum age: N/A
healthy volunteers: No
last name: Roberto Bertini
role: Principal Investigator
affiliation: IRCCS San Raffaele
last name: Cristina Carenzi
email: carenzi.cristina@hsr.it
last name: Roberto Bertini
phone: +390226437267
email: bertini.roberto@hsr.it
facility: 
status: Recruiting
contact: 
country: Italy
citation: Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum In: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.
PMID: 21296855
citation: Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004 Feb 15;100(4):738-45. doi: 10.1002/cncr.20025.
PMID: 14770429
citation: Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, Kaouk JH, Gill IS, Campbell SC. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010 Jul 1;116(13):3119-26. doi: 10.1002/cncr.25184.
PMID: 20564627
citation: Tada S, Yamagishi J, Kobayashi H, Hata Y, Kobari T. The incidence of simple renal cyst by computed tomography. Clin Radiol. 1983 Jul;34(4):437-9. doi: 10.1016/s0009-9260(83)80238-4.
PMID: 6872451
citation: Lane BR, Chen H, Morrow M, Anema JG, Kahnoski RJ. Increasing use of kidney sparing approaches for localized renal tumors in a community based health system: impact on renal functional outcomes. J Urol. 2011 Oct;186(4):1229-35. doi: 10.1016/j.juro.2011.05.081. Epub 2011 Aug 17.
PMID: 21849192
citation: Thompson RH, Kaag M, Vickers A, Kundu S, Bernstein M, Lowrance W, Galvin D, Dalbagni G, Touijer K, Russo P. Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol. 2009 Mar;181(3):993-7. doi: 10.1016/j.juro.2008.11.017. Epub 2009 Jan 16.
PMID: 19150552
citation: Dulabon LM, Lowrance WT, Russo P, Huang WC. Trends in renal tumor surgery delivery within the United States. Cancer. 2010 May 15;116(10):2316-21. doi: 10.1002/cncr.24965.
PMID: 20225227
citation: Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG; Practice Guidelines Committee of the American Urological Association. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct;182(4):1271-9. doi: 10.1016/j.juro.2009.07.004. Epub 2009 Aug 14. No abstract available.
PMID: 19683266
citation: Klinghoffer Z, Tarride JE, Novara G, Ficarra V, Kapoor A, Shayegan B, Braga LH. Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. Can Urol Assoc J. 2013 Mar-Apr;7(3-4):108-13. doi: 10.5489/cuaj.502.
PMID: 23671525
citation: Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, Weight CJ, Campbell SC. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007 Aug;178(2):429-34. doi: 10.1016/j.juro.2007.03.106. Epub 2007 Jun 11.
PMID: 17561141
citation: Remzi M, Ozsoy M, Klingler HC, Susani M, Waldert M, Seitz C, Schmidbauer J, Marberger M. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006 Sep;176(3):896-9. doi: 10.1016/j.juro.2006.04.047.
PMID: 16890647
citation: Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003 Dec;170(6 Pt 1):2217-20. doi: 10.1097/01.ju.0000095475.12515.5e.
PMID: 14634382
citation: Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S, Kirkali Z, Marberger M, Patard JJ, Staehler M, Uzzo RG. Contemporary management of small renal masses. Eur Urol. 2011 Sep;60(3):501-15. doi: 10.1016/j.eururo.2011.05.044. Epub 2011 Jun 1.
PMID: 21664040
citation: Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4. doi: 10.1093/jnci/djj362.
PMID: 16985252
citation: Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008 Jun;179(6):2146-51; discussion 2151. doi: 10.1016/j.juro.2008.01.101. Epub 2008 Apr 18.
PMID: 18423735
citation: Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, Jewett MA, Greenberg RE, Uzzo RG. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012 Feb 15;118(4):997-1006. doi: 10.1002/cncr.26369. Epub 2011 Jul 15.
PMID: 21766302
citation: Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009 Mar;181(3):1020-7; discussion 1027. doi: 10.1016/j.juro.2008.11.023. Epub 2009 Jan 16.
PMID: 19150563
citation: Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, Tanguay S, Rendon RA, Gleave ME, Drachenberg DE, Chow R, Chung H, Chin JL, Fleshner NE, Evans AJ, Gallie BL, Haider MA, Kachura JR, Kurban G, Fernandes K, Finelli A. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011 Jul;60(1):39-44. doi: 10.1016/j.eururo.2011.03.030. Epub 2011 Apr 1.
PMID: 21477920
citation: Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, Jewett MA, Klotz L, Rendon RA. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol. 2011 May;59(5):863-7. doi: 10.1016/j.eururo.2011.02.023. Epub 2011 Feb 22.
PMID: 21353376
citation: Ozsoy M, Klatte T, Waldert M, Remzi M. Surveillance for the management of small renal masses. Adv Urol. 2008;2008:196701. doi: 10.1155/2008/196701.
PMID: 18704192
citation: Patel N, Cranston D, Akhtar MZ, George C, Jones A, Leiblich A, Protheroe A, Sullivan M. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int. 2012 Nov;110(9):1270-5. doi: 10.1111/j.1464-410X.2012.11130.x. Epub 2012 May 4.
PMID: 22564495
citation: Barrisford GW, Singer EA, Rosner IL, Linehan WM, Bratslavsky G. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol. 2011;2011:658767. doi: 10.1155/2011/658767. Epub 2011 Aug 22.
PMID: 22312516
citation: Walther MM, Choyke PL, Glenn G, Lyne JC, Rayford W, Venzon D, Linehan WM. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999 May;161(5):1475-9. doi: 10.1016/s0022-5347(05)68930-6.
PMID: 10210376
citation: Ayati M, Nikfallah A, Jabalameli P, Najjaran Tousi V, Noroozi M, Jamshidian H. Extensive surgical management for renal tumors with inferior vena cava thrombus. Urol J. 2006 Fall;3(4):212-5.
PMID: 17559043
citation: Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.
PMID: 3558716
responsible party type: Principal Investigator
investigator affiliation: IRCCS San Raffaele
investigator full name: Roberto Bertini
investigator title: Principal investigator
mesh term: Kidney Neoplasms
mesh term: Carcinoma, Renal Cell
sharing ipd: Undecided